August 26, 2025 – The "2024 Shanghai Science and Technology Award Conference" was grandly held in Shanghai. The project "Development and Translational Application of Key Technologies in Gene Editing and Cell Therapy," jointly developed by BRL Medicine Inc. (referred to as "BRL Medicine") and the research team of Professors Mingyao Liu, Bing Du, and Dali Li from East China Normal University, was awarded the First Prize of the Shanghai Science and Technology Progress Award.

Professors Mingyao Liu (1st left) and Bing Du (2nd left) accepted the honor on behalf of the team.

The "Shanghai Science and Technology Progress Award" is one of the highest honors in Shanghai's scientific and technological field, recognizing individuals and organizations that have made significant breakthroughs or outstanding contributions in scientific research, technological development and innovation, achievement transformation, and high-tech industrialization. The award has strict selection criteria, emphasizing not only technological advancement and innovation but also practical application value, industrial impact, and tangible contributions to economic and social development. Projects awarded the First Prize represent international advanced or domestically leading levels in their respective fields, reflecting major scientific and technological achievements with significant social or economic benefits, and are highly recognized for their substantial value.

This award signifies that BRL Medicine's innovation capabilities and translational achievements in the field of cutting-edge biopharmaceutical technology have received dual recognition from both the government and academia. As a core contributing unit of the award-winning project, BRL Medicine leveraged its extensive expertise in gene editing technology and cell therapy product development. Through close collaboration with the research team of Professors Mingyao Liu, Bing Du, and Dali Li from East China Normal University, the team overcame multiple technical bottlenecks after years of dedicated efforts, achieving original breakthroughs and clinical translation in three core technologies.

From following to leading, from laboratory research to clinical translation and future commercialization, the achievements of this project have not only enabled China to achieve a "corner overtaking" in the field of gene and cell therapy but also hold the potential to make "untreatable" diseases a thing of the past and bring "prohibitively expensive drugs" within reach of ordinary people. Where technology and humanity converge, every precise leap of gene editing resonates with the era's strongest note of prioritizing life. In the future, BRL Medicine will continue to focus on the field of gene and cell therapy, striving to become a globally leading innovative pharmaceutical company and contributing technological strength to the realization of the "Healthy China" strategy.

Mingyao Liu, Bing Du, Yuxuan Wu, Dali Li, Jiqin Zhang, Binghe Tan, Na Zhang, Jiaoyang Liao, Liren Wang, Juliang Qin

Award-Winning Contributing Institutions:

East China Normal University

BRL Medicine Inc.

YolTech Therapeutics